aTyr Pharma, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-19$1.05 RISE2026-05-13$0.40 PEAK2026-05-14$0.56 84d | -62.3% 83d | Missed | Missed | — | — | +41.4% 1d | Missed |
DROP2026-02-19$1.05 RISE2026-03-30$0.73 PEAK2026-05-06$1.04 76d | -30.4% 39d | Missed | Missed | — | — | +42.3% 37d | Missed |
DROP2025-10-10$1.06 RISE2026-01-28$0.67 PEAK2026-02-19$1.05 132d | -36.4% 110d | Missed | Missed | — | — | +55.8% 22d | Missed |
DROP2025-07-23$6.61 RISE2025-11-20$0.65 PEAK2026-02-19$1.05 211d | -90.2% 120d | Missed | Missed | — | — | +61.3% 91d | Missed |
DROP2025-07-23$6.61 RISE2025-10-01$0.69 PEAK2025-10-10$1.06 79d | -89.6% 70d | Missed | Missed | — | — | +53.6% 9d | Missed |
DROP2025-02-20$4.43 RISE2025-05-15$3.00 PEAK2025-07-23$6.61 153d | -32.3% 84d | Missed | Missed | — | — | +120.3% 69d | Missed |
DROP2025-02-20$4.43 RISE2025-04-04$2.62 PEAK2025-06-10$5.50 110d | -40.9% 43d | Missed | Missed | — | — | +109.9% 67d | Missed |
DROP2024-11-13$3.52 RISE2024-11-15$2.91 PEAK2025-01-03$3.98 51d | -17.5% 2d | Missed | Missed | — | — | +37.0% 49d | Missed |
DROP2024-07-25$2.23 RISE2024-10-01$1.72 PEAK2024-12-26$3.77 154d | -22.9% 68d | Missed | Missed | — | — | +119.2% 86d | Missed |
DROP2024-07-25$2.23 RISE2024-09-25$1.72 PEAK2024-12-02$3.56 130d | -22.9% 62d | Missed | Missed | — | — | +107.0% 68d | Missed |
DROP2024-05-20$2.07 RISE2024-06-25$1.46 PEAK2024-07-25$2.23 66d | -29.5% 36d | Missed | Missed | — | — | +52.7% 30d | Missed |
DROP2024-03-21$2.02 RISE2024-04-30$1.57 PEAK2024-07-25$2.23 126d | -22.3% 40d | Missed | Missed | — | — | +42.0% 86d | Missed |
DROP2024-03-21$2.02 RISE2024-04-26$1.57 PEAK2024-05-20$2.07 60d | -22.3% 36d | Missed | Missed | — | — | +31.8% 24d | Missed |
DROP2024-02-16$2.02 RISE2024-03-08$1.59 PEAK2024-05-20$2.07 94d | -21.3% 21d | Missed | Missed | — | — | +30.2% 73d | Missed |
DROP2023-07-21$2.07 RISE2023-11-14$1.11 PEAK2024-02-08$1.97 202d | -46.4% 116d | Missed | Missed | — | — | +77.5% 86d | Missed |
1–15 / 28 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
aTyr Pharma, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 10.79 million compared to USD 14.88 million a year...
aTyr Pharma (NASDAQ:ATYR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the
SAN DIEGO — SAN DIEGO — Atyr Pharma Inc. on Friday reported a loss of $10.8 million in its first quarter. The San Diego-based company said it had a loss of 11 cents per share. The company's...
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in...
2026-05-14. The following slide deck was published by aTyr Pharma, Inc.
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in...
SAN DIEGO, May 13, 2026 -- aTyr Pharma, Inc. , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase...
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III Results May 11, 2026 4:30 PM...
Presentation Operator MessageOperator Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma conference call. [Operator Instructions] As a reminder, this conference is being recorded
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting. President and CEO Dr. Sanjay Shukla said the meeting, held in mid-April with official minu
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting. President and CEO Dr. Sanjay Shukla said the meeting, held in mid-April with official minu
Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint and KSQ-Lung as key secondary endpoint.Management to host conference call and webcast today at 4:30pm ET / 1:30pm PT. SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“a
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATYR | -34.89% | -45.15% | -30.65% | -87.85% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -37.86% | -39.44% | -27.21% | -100.54% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 14.71M | $11.47M | 0.00% | Unchanged | 2026-03-31 |
| StateStreet | passive | 1.75M | $1.37M | 0.00% | Added+1.7% | 2026-03-31 |
| TwoSigma | quant | 1.14M | $892.76K | 0.00% | Added+151.9% | 2026-03-31 |
| RenTech | quant | 40.5K | $31.61K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 46.1K | $36 | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.12 | — | — |
| 2026-05-15 | -0.14 | -0.11 | +20.00% |
| 2026-03-05 | -0.17 | -0.14 | +20.00% |
| 2025-11-06 | -0.18 | -0.26 | -40.88% |
| 2025-08-07 | -0.18 | -0.22 | -20.40% |
| 2025-05-07 | -0.19 | -0.17 | +10.53% |
| 2025-03-13 | -0.23 | -0.18 | +20.35% |
| 2024-11-07 | -0.22 | -0.23 | -4.55% |
| 2024-08-13 | -0.24 | -0.23 | +3.36% |
| 2024-05-02 | -0.25 | -0.23 | +8.00% |
| 2024-03-14 | -0.24 | -0.25 | -5.04% |
| 2023-11-09 | -0.22 | -0.20 | +10.11% |
| 2023-08-09 | -0.27 | -0.22 | +19.71% |
| 2023-05-09 | -0.41 | -0.29 | +29.61% |
| 2023-03-09 | -0.48 | -0.26 | +45.83% |
| 2022-11-10 | -0.46 | -0.46 | +0.54% |